Cargando…

Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension

The management of pulmonary arterial hypertension (PAH) has become more complex in recent years because of increased pharmacotherapy options and longer patient survival with increasing numbers of comorbidities. As such, more opportunities exist for drug-drug interactions between PAH-targeted medicat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Sheryl, Hoang, Heather B., Yang, Jenny Z., Papamatheakis, Demosthenes G., Poch, David S., Alotaibi, Mona, Lombardi, Sandra, Rodriguez, Cynthia, Kim, Nick H., Fernandes, Timothy M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Chest Physicians 2022
Materias:	Pulmonary Vascular: CHEST Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773230/ https://www.ncbi.nlm.nih.gov/pubmed/35841932 http://dx.doi.org/10.1016/j.chest.2022.06.042

Ejemplares similares

Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension
por: Yang, Jenny, et al.
Publicado: (2023)

Pulmonary Thrombosis and Thromboembolism in COVID-19
por: Poor, Hooman D.
Publicado: (2021)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Letter to the Editor regarding “Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?”
por: Fernandes, Timothy M., et al.
Publicado: (2020)

Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience
por: Hoole, Stephen P, et al.
Publicado: (2020)

Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension
por: Suzuki, Sho, et al.
Publicado: (2022)

Prevalence and haemodynamic profiles of pulmonary hypertension in cardiac amyloidosis
por: Slivnick, Jeremy, et al.
Publicado: (2022)

Efficacy of cardiac rehabilitation after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Fukui, Shigefumi, et al.
Publicado: (2016)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

COVID-19 AS A PRIMARY CAUSE OF PULMONARY ARTERIAL HYPERTENSION
por: RAVAL, ABHIJIT, et al.
Publicado: (2021)

Prevalence of pulmonary hypertension in mitral regurgitation and its influence on outcomes
por: Ratwatte, Seshika, et al.
Publicado: (2023)

Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy
por: Ghio, Stefano, et al.
Publicado: (2016)

Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19
por: Pagnesi, Matteo, et al.
Publicado: (2020)

Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response
por: Goh, Ze Ming, et al.
Publicado: (2022)

Right heart function during simulated altitude in patients with pulmonary arterial hypertension
por: Seccombe, Leigh M, et al.
Publicado: (2017)

Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension
por: Chouvarine, Philippe, et al.
Publicado: (2020)

Continuous long-term heart rate variability and risk assessment in pulmonary hypertension
por: Andersen, Mads Ørbæk, et al.
Publicado: (2023)

Effects of oral sildenafil on exercise capacity in children with pulmonary arterial hypertension: a randomised trial
por: Russell, Stuart, et al.
Publicado: (2019)

Prognostic relevance of the right ventricular myo-mechanical index (RV-MMI) in patients with precapillary pulmonary hypertension
por: Greiner, Sebastian, et al.
Publicado: (2018)

Predicting Group II pulmonary hypertension: diagnostic accuracy of the H2FPEF and OPTICS scores in Scotland
por: Stubbs, Harrison, et al.
Publicado: (2022)

Characteristics and in-hospital outcomes of patients undergoing balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a time-trend analysis from the Japanese nationwide registry
por: Minatsuki, Shun, et al.
Publicado: (2021)

Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review
por: Varela, Daniel L, et al.
Publicado: (2018)

Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study
por: Gerhardt, Felix, et al.
Publicado: (2017)

A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines
por: Dardi, Fabio, et al.
Publicado: (2021)

Outcomes of cardiopulmonary resuscitation in patients with pulmonary arterial hypertension
por: Yang, Jenny Z., et al.
Publicado: (2022)

Evolution of randomized, controlled studies of medical therapy in chronic thromboembolic pulmonary hypertension
por: Kim, Nick H., et al.
Publicado: (2021)

Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
por: Han, Yuchi, et al.
Publicado: (2018)

Diagnostic accuracy of CT pulmonary angiography in suspected pulmonary hypertension
por: Swift, Andrew J., et al.
Publicado: (2020)

The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension
por: Haddad, Francois, et al.
Publicado: (2022)

The WHO classification of pulmonary hypertension: A case-based imaging compendium
por: Ryan, John J., et al.
Publicado: (2012)

Mechanisms of ECG signs in chronic obstructive pulmonary disease
por: Larssen, Marte Strømsnes, et al.
Publicado: (2017)

BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis
por: McCarthy, Breanne E., et al.
Publicado: (2022)

ACUTE PULMONARY EMBOLISM AND MYOCARDIAL INJURY IN COVID-19 PATIENT
por: Alfaki, Musaab, et al.
Publicado: (2020)

SADDLE PULMONARY EMBOLISM WITH CRITICAL LIMB ISCHEMIA IN COVID-19
por: MAHGOUB, AHMED, et al.
Publicado: (2021)

Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency
por: Sweatt, Andrew J., et al.
Publicado: (2021)

Quantification of Arterial and Venous Morphologic Markers in Pulmonary Arterial Hypertension Using CT Imaging
por: Rahaghi, Farbod N., et al.
Publicado: (2021)

MASSIVE PULMONARY EMBOLISM TREATED WITH THROMBOLYSIS IN COVID-19: A CASE SERIES
por: Alarcon-Calderon, Amarilys, et al.
Publicado: (2020)

DIFFERENCES IN CLINICAL CHARACTERISTICS, TREATMENT, AND OUTCOME OF PULMONARY EMBOLISM ACCORDING TO COVID-19 STATUS
por: KELTY, CATHERINE, et al.
Publicado: (2022)

Cardiac Effort to Compare Clinic and Remote 6-Minute Walk Testing in Pulmonary Arterial Hypertension
por: Lachant, Daniel, et al.
Publicado: (2022)

Radiological differences between chronic thromboembolic pulmonary disease (CTEPD) and chronic thromboembolic pulmonary hypertension (CTEPH)
por: Capone, Carmine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_urrmutikmd1j4t26vg7khtgohq